Background: Preventing preeclampsia is crucial to lowering maternity mortality and morbidity rates globally. The use of to enhance maternal, perinatal, or newborn outcomes and avoid preeclampsia has been investigated in most recent studies. The outcomes remain up for debate, though.
Goals: To assess how well pravastatin works to keep pregnant women from developing preeclampsia.
Methods: To determine the likelihood of preeclampsia, this research included an analysis of randomized controlled trials (RCTs) of trials incorporating pregnant women given pravastatin versus placebo. PubMed, Science Direct, EMBASE, PROQUEST, and SCOPUS were searched for relevant literature. Five investigations were first found to match the inclusion criteria; however, two of them had to be disqualified since they were treatment studies, and one minor research only utilized pravastatin for just a few weeks, keeping just 2 articles for statistical analysis.
Results: Pravastatin prescription was linked to a lower incidence of preterm delivery (OR: 0.31; 95% CI: 0.16-0.58; p<0.01) and preeclampsia (OR: 0.51; 95% CI: 0.29-0.90; p=0.02). There was no difference in the risk of PE & fetal growth restriction and severe characteristics. Preventive pravastatin was linked to a notable and significant decrease in premature preeclampsia rates (OR: 0.034; 95% CI: 0.202-0.905), according to the only trial (INOVASIA) that examined premature preeclampsia. Pravastatin-treated pregnant women experienced improved perinatal outcomes, including reduced birth weight, Apgar scores, NICU admission, and respiratory distress syndrome.
Conclusions: Pravastatin may help pregnant women avoid preeclampsia, early delivery, and perinatal illness.